Summary Verrica Pharmaceuticals Inc (Verrica) is a clinical-stage medical dermatology company that discovers, develops and commercializes therapeutics for the treatment of skin diseases.The company’s lead product candidate, VP-102, is in two phase 3 clinical trials for the treatment of molluscum contagiosum, a high contagious and primarily pediatric viral skin disease; and in a Phase 2 clinical trial for the treatment of common warts.
Verrica is headquartered in West Chester, Pennsylvania, the US.
Verrica Pharmaceuticals Inc (VRCA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Topical Absorbable Hemostats - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Topical Absorbable Hemostats - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Topical Absorbable Hemostats pipeline products with comparative...
Keloids - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Keloids - Pipeline Review, H1 2020, provides an overview of the Keloids (Dermatology) pipeline landscape. Keloids are a growth of extra scar tissue where the skin has healed after an...
Wounds - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H1 2020, provides an overview of the Wounds (Dermatology) pipeline landscape. Wound is a breakdown in the protective function of the skin (the loss of continuity...
Integrin Beta 7 - Pipeline Review, H1 2020 Summary Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium...
200 pages •
By The Business Research Company
• Jul 2020
Major players in the COVID19 drug-associated APIs market are Dr. Reddy’s Laboratories, Lianyungang Guike Pharmaceutical, Alembic Pharmaceutical, Wockhardt Ltd, Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical (Haimen) Co Ltd, and Yatai Pharma. The global COVID-19 associated API market is expected to...
200 pages •
By The Business Research Company
• Jul 2020
Major players in the convalescent plasma therapy market are Bio Farma, Grifols, Hilton Pharma, Biotest, BPL, LFB, Octapharma, CSL Behring, Takeda Pharmaceutical Company Limited, and Orthosera Kft. The global convalescent plasma therapy market is expected to grow from $20.3 million in 2019 to $26.4 million by the end of 2020 at a compound...
213 pages •
By Asia Market Information & Development Company
• Jun 2020
China’s demand for Respiratory Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...